Cyclone® 70 will be used as a high energy, high intensity proton “driver” for a large science project for rare isotopes
Louvain-la-Neuve, Belgium 5h 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of solutions for the diagnosis and treatment of cancer, today announces it has signed a formal contract with the Institute for Basic Science (IBS) to install a Cyclone® 70 system in Daejeon, South Korea. The installation of the system is worth between USD 13 and USD 16 million to IBA and the project is fully financed.
Bruno Scutnaire, President of RadioPharma Solutions at IBA, commented: “We are delighted that the Institute for Basic Science has selected our Cyclone® 70 system. It will be the fifth cyclotron of its kind installed worldwide. The Cyclone® 70 will use its energized proton beam to produce heavier ions that will be used after further acceleration to study new rare isotopes.”
IBS is constructing equipment and facilities for the Rare isotope Accelerator complex for ON-line experiments (RAON). RAON is a large basic science research facility built around a heavy-ion accelerator. When completed, it will be a key pillar of the International Science and Business Belt (ISBB). This will be an optimal facility to produce and study new rare isotopes, so the global scientific community is closely following its progress.
“We selected IBA for its leading technology and unique know-how in developing high energy 70 MeV cyclotrons,” said Youngkwan Kwon, Associate Director of Rare Isotope Science Project at the Institute for Basic Science. “The Cyclone®70 will be one of the drivers of the RAON facility. Scientists have discovered approximately 3,000 isotopes to date, but they believe an additional 7,000 isotopes have yet to be discovered, presenting unlimited potential for rare isotope science. When the operation of RAON begins, new research opportunities will open up in various areas, such as research into the origin of elements, discovery of new rare isotopes and the study of their structure, and applied research in material and biomedical sciences.”
***ENDS***
About the Institute for Basic Science
IBS was established in November 2011 as Korea’s first dedicated basic science research institute. By studying the fundamental principles of nature, basic science is essential in creating new knowledge from which significant societal transformations are derived. IBS promotes the highest quality of research that will increase the national basic science capacity and generate new opportunities for this nation.
IBS specializes in long-term projects that require large groups of researchers. As research in the 21st century requires more interdisciplinary collaborations from larger groups of people, scientists at IBS work together in the same laboratory base with a long-term perspective on research. IBS promote autonomy in research. IBS has launched 30 research centers as of June 2019. There are nine physics, two mathematics, six chemistry, seven life science, one earth science, and five interdisciplinary research centers.
About IBA Radiopharma Solutions
Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them with global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com
For further information, please contact:
IBA
Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas Ralet
Head of Corporate Communication
+32 10 475 890
communication@iba-group.com
For media and investor enquiries:
Consilium Strategic Communications
Amber Fennell, Angela Gray, Lizzie Seeley
+44 (0) 20 3709 5700
IBA@consilium-comms.com